Description: TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Home Page: www.tcr2.com
TCRR Technical Analysis
100 Binney Street
Cambridge,
MA
02142
United States
Phone:
617 949 5200
Officers
| Name | Title |
|---|---|
| Dr. Garry E. Menzel M.B.A., Ph.D. | Pres, CEO & Director |
| Dr. Patrick A. Baeuerle Ph.D. | Founder & Member of the Advisory Board |
| Mr. Peter Olagunju | Chief Technical Officer |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer |
| Mr. Richard Roomberg | VP of Corp. Controller |
| Mr. Eric M. Sullivan CPA | Chief Financial Officer |
| Carl Mauch | Sr. Director of Investor Relations & Corp. Communications |
| Ms. Margaret Siegel J.D. | Head of Legal & Corp. Sec. |
| Dr. Angela Justice Ph.D. | Chief People Officer |
| Dr. Rosemary Harrison Ph.D. | Chief Bus. & Strategy Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.222 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-02-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |